| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000030830 |
| Receipt No. | R000035189 |
| Official scientific title of the study | Steroids inhalation therapy in chronic eosinophilic pneumonia |
| Date of disclosure of the study information | 2018/01/16 |
| Last modified on | 2018/01/16 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Steroids inhalation therapy in chronic eosinophilic pneumonia | |
| Title of the study (Brief title) | Eosinophilic pneumonia | |
| Region |
|
|
| Condition | |||
| Condition | Eosinophilic pneumonia | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To examine lebel and site of inflamation in lung. |
| Basic objectives2 | Others |
| Basic objectives -Others | Efficacy of ICS in Eosinophilic Pnemonia. |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | CD25 expression on CD4-positive T-lymphocytes was also increased (25.5 %) in the BALF compared to that on those in the peripheral blood (15.5 %). |
| Key secondary outcomes | We tried many ICSs on remmission and acute phase but obtained enough effect in eosinophilic pneumonia. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | In December 1999, a 15-year-old girl was referred to Habikino hospital for evaluation of respiratory symptoms. BALF, Peripheral blood.process of treatments with ICS. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Eosinophilic pneumonia, a case report. | |||
| Key exclusion criteria | Nothing | |||
| Target sample size | 1 | |||
| Research contact person | |
| Name of lead principal investigator | Norihide Murayama |
| Organization | Murayama Pediatrics |
| Division name | Pediatrics |
| Address | 3-2-33 Nagayoshi-Nagahara-Higashi Hirano-ku Osaka-shi Osaka Japan |
| TEL | 06-6790-8835 |
| norihide99@yahoo.co.jp | |
| Public contact | |
| Name of contact person | Norihide Murayama |
| Organization | Murayama Pediatrics |
| Division name | Pediatrics |
| Address | 3-2-33 Nagayoshi-Nagahara-Higashi Hirano-ku Osaka |
| TEL | 06-6790-8835 |
| Homepage URL | |
| norihide99@yahoo.co.jp | |
| Sponsor | |
| Institute | Murayama Pediatrics |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Murayama Pediatrics |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | Eosinophils were increased in both the BALF (65 %) and peripheral blood (33 %). HLADR expression was increased on CD4-positive T-lymphocytes in the BALF (62.8 %) compared to that on those in the peripheral blood (6.4 %). CD25 expression on CD4-positive T-lymphocytes was also increased (25.5 %) in the BALF compared to that on those in the peripheral blood (15.5 %). |
| Other related information | We tried some ICS therapies for more than ten years. But I could not gain expected effect by any inhaled steroids. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035189 |